More about

Eosinophilic Esophagitis

News
May 20, 2022
1 min read
Save

FDA approves first treatment for eosinophilic esophagitis in the US

The FDA has granted approval for dupilumab for the treatment of eosinophilic esophagitis for adult and pediatric patients aged 12 years and older, according to a press release.

News
April 04, 2022
1 min read
Save

FDA accepts supplemental biologics license application for Dupixent for EoE

FDA accepts supplemental biologics license application for Dupixent for EoE

Regeneron Pharmaceuticals Inc. and Sanofi announced that the FDA accepted for priority review a supplemental biologics license application for Dupixent 300 mg for adults and children aged 12 years and older with eosinophilic esophagitis.

News
April 01, 2022
1 min read
Save

Top in GI: AI-assisted colonoscopy, FDA denial of budesonide for eosinophilic esophagitis

Top in GI: AI-assisted colonoscopy, FDA denial of budesonide for eosinophilic esophagitis

A new study showed that artificial intelligence-assisted colonoscopy increased the adenoma detection rate in patients at average risk for colorectal cancer. It was the top story in gastroenterology last week.

News
March 28, 2022
2 min read
Save

Dupilumab induces eosinophilic esophagitis remission among children with atopic conditions

Dupilumab induces eosinophilic esophagitis remission among children with atopic conditions

Dupilumab effectively induced remission of esophageal disease among children with eosinophilic esophagitis treated with the agent for atopic conditions, according to a study published in Annals of Allergy, Asthma & Immunology.

News
March 22, 2022
9 min read
Save

Is FDA approval in sight for emerging EoE therapies?

Is FDA approval in sight for emerging EoE therapies?

Over the years, there have been many advances in the pathologic understanding of eosinophilic esophagitis, but FDA-approved treatment options have lagged.

News
March 22, 2022
4 min read
Save

Budesonide for EoE: Why the FDA denial is so hard to swallow

Budesonide for EoE: Why the FDA denial is so hard to swallow

In December 2021, the FDA issued a complete response letter to Takeda Pharmaceutical Company for its new drug application for budesonide oral suspension for the treatment of eosinophilic esophagitis in adolescents and adults.

News
February 27, 2022
3 min read
Save

Weekly dupilumab may induce histologic remission of eosinophilic esophagitis

Weekly dupilumab may induce histologic remission of eosinophilic esophagitis

PHOENIX — Dupilumab significantly improved swallowing ability and reduced eosinophils in the esophagus, indicating histologic remission, compared with placebo, according to results from the phase 3 LIBERTY-EoE-TREET study.

News
January 04, 2022
1 min read
Save

FDA rejects new drug application from Takeda for budesonide for EoE

FDA rejects new drug application from Takeda for budesonide for EoE

Takeda Pharmaceutical Company Limited announced it received an FDA complete response letter in response to its new drug application for TAK-721 for the treatment of eosinophilic esophagitis, according to a release.

News
December 16, 2021
1 min read
Save

Budesonide improves histologic, symptom response in pediatric EoE

Budesonide improves histologic, symptom response in pediatric EoE

Budesonide oral suspension improved histologic, endoscopic and symptom response compared with placebo among pediatric patients with eosinophilic esophagitis, according to a study.

News
December 06, 2021
4 min read
Save

Q&A: Dupilumab may help patients with eosinophilic esophagitis return to ‘normal’ diet

Q&A: Dupilumab may help patients with eosinophilic esophagitis return to ‘normal’ diet

Researchers at Children’s Hospital of Philadelphia have recently been gifted $2 million to begin conducting a clinical trial studying the effects of dupilumab on patients with eosinophilic esophagitis.

View more